TP53 mutations, particularly the hot spot mutations R249S and V157F, are associated with poor prognosis for patients with HCC. The acquisition of stem cell-like gene expression traits might …

2025年1月29日 · Telomerase reverse transcriptase (TERT) promoter mutations (TERTpm) and cellular tumor antigen p53 mutations (TP53m) have been frequently documented in HCC, but …

2023年7月27日 · Here, we discovered that the simultaneous mutations in TP53 and activation of c-MET occur in ~20% of human HCCs, and these patients show a poor prognosis. …

为了系统地评估HCC中TP53错义突变对转录激活的潜在影响，该研究对结合TP53及赖氨酸H3K27ac的全基因组进行了数据分析，并对4种TP53突变体（L3环及非L3环各两个）进行 …

2024年1月19日 · Our research introduces a novel drug target for TP53-mutant HCC cells via mitochondrial ATP, addressing the limitation of Nultin-3 as a standalone treatment that does …

TP53 mutation is strongly related to the immune microenvironment in HCC. Our IPM, which is sensitive to TP53 mutation status, may have important implications for identifying subgroups of …

TP53-induced glycolysis and apoptosis regulator (TIGAR) is a p53 target protein that has critical roles in glycolysis and redox balance. The reports about the effect of TIGAR on prognosis and …

2019年3月16日 · TP53 mutation is the most common mutation in hepatocellular carcinoma (HCC), and it affects the progression and prognosis of HCC. We investigated how TP53 …

2 天之前 · 编者按在APASL 2025大会上，广西医科大学第一附属医院江建宁教授团队展示了其在非病毒性肝病、HBV相关肝细胞癌（HCC）、HBV母婴阻断等领域的11项 ...

2024年8月12日 · Abstract. Introduction:TP53-induced glycolysis and apoptosis regulator (TIGAR) is a p53 target protein that has critical roles in glycolysis and redox balance. The reports about …